Answers are grounded in this paper and cite their sources.
Phase I trial evaluates Ritanine's pharmacokinetics in subjects with hepatic impairment, suggesting dosage adjustment may not be needed.
Objectives Ritanine (HR20013) is a fixed-dose combination of fosrolapitant (218 mg, a rolapitant prodrug) and palonosetron (0.25 mg), designed to enhance rolapitant’s solubility and reduce allergic reactions associated with intravenous administration. Metabolized primarily by the liver, hepatic impairment may affect its pharmacokinetics (PK) and safety. Methods This nonrandomized, open-label, single-dose study evaluated the effect of moderate hepatic impairment on Ritanine’s PK and safety. Eight subjects with moderate hepatic impairment and eight healthy controls each received a single intravenous infusion. Results Compared with healthy controls, the geometric least-squares mean ratios for C max , AUC 0-t , and AUC 0 − ∞ in subjects with moderate hepatic impairment were 1.27, 1.51, and 1.51 for fosrolapitant; 0.61, 1.15, and 1.24 for rolapitant; 0.74, 0.85, and 1.13 for metabolite M19; and 0.90, 1.77, and 1.46 for palonosetron, respectively. Hepatic impairment did not significantly alter the T max or elimination half-life (t 1/2 ) of the above components. Ritanine exhibited good safety and tolerability in this study. Conclusion Moderate hepatic impairment has a minimal impact on the pharmacokinetics of Ritanine, suggesting that no dosage adjustment is necessary for patients with moderate hepatic impairment in clinical practice. Clinical Trail Registration http://www.chinadrugtrials.org.cn , identifier CTR20233771.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: